Unibar Corporation Secures European Patent for CapsiClear Eye Health Ingredient Targeting Glaucoma Treatment
Key Insights
Unibar Corporation (search) received a European patent on July 2, 2025, for CapsiClear (search), a Capsicum annum extract (search) standardized to 50% capsanthin (search) for eye health applications.
The patent covers CapsiClear (search)'s use in reducing intraocular pressure associated with normal tension glaucoma (search), primary open angle glaucoma (search), and angle closure glaucoma (search) across ten European markets.
Clinical studies suggest CapsiClear (search) may support healthy ocular pressure within normal ranges and also promote tear production and eye hydration for dry eye (search) relief.
Unibar Corporation (search) announced that it has secured a European patent for CapsiClear (search), a novel eye health ingredient derived from Capsicum annum extract (search), marking a significant milestone in the company's expansion into international markets. The patent, granted on July 2, 2025, covers the ingredient's unique composition for therapeutic applications in glaucoma (search) treatment.
Patent Coverage and Therapeutic Applications
The European patent specifically covers CapsiClear (search)'s use "for the reduction of intraocular pressure associated with normal tension glaucoma (search), primary open angle glaucoma (search), angle closure glaucoma (search), and/or combinations thereof." The patent extends across ten key European markets, including the United Kingdom, Italy, France, Switzerland, Poland, Ireland, Greece, Germany, Spain, and Hungary.
CapsiClear (search) is standardized to contain 50% capsanthin (search), a carotenoid compound that clinical studies suggest may support healthy ocular pressure within normal ranges. According to the company, the ingredient may also support tear production and eye hydration, potentially benefiting individuals suffering from dry eye (search) conditions.
Market Opportunity and Clinical Relevance
The patent comes at a time when dry eye (search) prevalence in Europe is substantial, with estimates suggesting that 10-30% of the population is impacted, according to Unibar. The company identifies longer screen time in daily life as a major contributing factor, along with other systemic health issues, poor sleep, prolonged outdoor exposure, and effects of aging.
"We are thrilled to receive this European patent for CapsiClear (search) which underscores our long-standing commitment to best-in-class eye health research," said Sevanti Mehta, president of Unibar. "This decision validates the innovation behind Unibar's portfolio and our continued efforts to deliver effective, natural solutions for eye wellness backed by both modern science and ancient tradition."
Commercial Strategy and Market Launch
With the patent secured, Unibar Corporation (search) is working on targeted market campaigns to introduce CapsiClear (search) to global partners, formulators, and health professionals. The company plans to launch products ahead of major industry conferences scheduled for fall 2025.
Doug Lynch, CEO of MarketWell Nutrition Inc. (search), which serves as the commercial representative for Unibar Corporation (search), expressed enthusiasm about the market potential. "We are very excited to help bring Unibar's unparalleled botanical science to leading consumer health brands worldwide," Lynch said. "Patented, market-ready CapsiClear (search) will bring true product differentiation to all our brand partners."
The European patent represents a crucial step in Unibar's strategy to establish CapsiClear (search) as a differentiated ingredient in the competitive eye health supplement market, providing the company with intellectual property protection across major European territories as it seeks to expand its international presence.